■Polidocanol硬化疗法治疗有或没有病理性骨折的动脉瘤性骨囊肿(ABC)一直是争论的话题。虽然一些研究推荐病灶内刮治作为首选治疗方法,其他人建议病灶内硬化剂作为一种有效的替代品。
■本研究评估了28例ABCs患者使用以脊髓灰质炎为基础的经皮硬化剂治疗,其中病理性骨折8例。根据囊肿的临床和放射学评估,患者每四周接受一次注射,该研究评估了治疗的结果和并发症。
■A组(无病理性骨折),17个病变中有14个(82.4%)已治愈,无任何明显残留病变。17例患者中有3例(17.6%)需要进一步的手术治疗,并接受刮除和植骨治疗,确定。3例患者出现轻微的局部炎症反应,在没有干预的情况下在3-4天内解决。B组,8例(100%)病理性骨折患者病灶均愈合为1级愈合,没有任何明显的残留病变。一名患者出现了与麻醉相关的并发症(延迟恢复),该并发症在一小时内消退。没有任何残余效应。在最后的后续行动中,所有患者均未出现复发.
■该研究得出结论,脊髓灰质炎硬化疗法是ABCs患者的有效治疗选择,有或没有病理性骨折,并且由于其低侵入性,有可能成为病理性骨折的新治疗选择,低发病率,和负担能力。然而,需要进一步的研究来证实脊髓灰质炎硬化疗法在较大患者人群中的疗效,并将其与其他治疗方案的有效性进行比较.
UNASSIGNED: Polidocanol sclerotherapy in the treatment of aneurysmal bone cysts (ABCs) with or without pathological fractures has been a topic of debate. While some studies recommend intralesional curettage as the preferred treatment, others suggest intralesional sclerosants as an effective alternative.
UNASSIGNED: This
study evaluates the use of polidocanol-based percutaneous sclerosant therapy in 28 patients with ABCs, of which 8 patients had pathological fracture. The patients received injections every four weeks based on clinical and radiological evaluation of the cyst, and the
study assessed the results and complications of the treatment.
UNASSIGNED: In group A (without pathological fractures), 14 out of 17 (82.4 %) lesions healed without any significant residual lesion. Three out of 17 (17.6 %) patients required further surgical intervention and were treated by curettage and bone grafting, definitively. Minor local inflammatory reaction was observed in 3 patients, which resolved without intervention within 3-4 days. In group B, all the 8 patients (100 %) with pathological fracture in their lesions healed as Grade 1 healing, without any significant residual lesion. One patient developed an episode of anesthesia related complication (delayed recovery) which resolved within an hour, without any residual effect. At final follow up, no recurrence was seen in any patient.
UNASSIGNED: The
study concludes that polidocanol sclerotherapy is an effective treatment option for patients with ABCs, with or without pathological fractures, and has the potential to become the new treatment of choice for pathological fractures due to its low invasiveness, low morbidity, and affordability. However, further research is needed to confirm the efficacy of polidocanol sclerotherapy in larger patient populations and to compare its effectiveness with other treatment options.